The 36-month beta value for BDRX is also noteworthy at 0.97. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The average trading volume of BDRX on July 04, 2025 was 2.54M shares.
BDRX stock’s latest price update
The stock of Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) has decreased by -2.43% when compared to last closing price of $0.88.Despite this, the company has seen a loss of -7.43% in its stock price over the last five trading days. globenewswire.com reported 2025-06-27 that June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company’s shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company’s website at https://biodexapharma.com/investors/corporate-governance//#agms.
BDRX’s Market Performance
Biodexa Pharmaceuticals Plc ADR (BDRX) has experienced a -7.43% fall in stock performance for the past week, with a -25.98% drop in the past month, and a -44.24% drop in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 9.63% for BDRX. The simple moving average for the past 20 days is -12.59% for BDRX’s stock, with a -75.95% simple moving average for the past 200 days.
Analysts’ Opinion of BDRX
Many brokerage firms have already submitted their reports for BDRX stocks, with Ladenburg Thalmann repeating the rating for BDRX by listing it as a “Buy”. The predicted price for BDRX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on February 08, 2024 of the previous year 2024.
BDRX Trading at -27.30% from the 50-Day Moving Average
After a stumble in the market that brought BDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.93% of loss for the given period.
Volatility was left at 9.63%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares sank -25.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.67% lower at present.
During the last 5 trading sessions, BDRX fell by -7.44%, which changed the moving average for the period of 200-days by -91.66% in comparison to the 20-day moving average, which settled at $0.9823. In addition, Biodexa Pharmaceuticals Plc ADR saw -96.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Biodexa Pharmaceuticals Plc ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for BDRX
Current profitability levels for the company are sitting at:
- -96.3% for the present operating margin
- -26.12% for the gross margin
The net margin for Biodexa Pharmaceuticals Plc ADR stands at -82.16%. The total capital return value is set at -0.82%. Equity return is now at value -89.21%, with -45.75% for asset returns.
Based on Biodexa Pharmaceuticals Plc ADR (BDRX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -10.66. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -163.12.
Currently, EBITDA for the company is -7.16 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of -11.34. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.75.
Conclusion
In summary, Biodexa Pharmaceuticals Plc ADR (BDRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
